Phaseline

Targets › TRHR

TRHR (Thyrotropin-releasing hormone receptor): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Mar 2027.

Receptor for thyrotropin-releasing hormone (TRH). Upon ligand binding, this G protein-coupled receptor triggers activation of the phosphatidylinositol (IP3)-calcium-protein kinase C (PKC) pathway. (UniProt, P34981)

Open in Phaseline: the race on TRHR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kissei PharmaceuticalRovatirelin (KPS-0373)
Thyrotropin-releasing hormone receptor agonist
TRHRPhase 3Spinocerebellar DegenerationMar 2027

Conditions

Spinocerebellar Degeneration (1)

Modalities

small molecule (1)

Companies

Kissei Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.